March 11 - A gene therapy biotech's quiet ascent, Bluebird details cancer case and Vertex's cell therapy

Bluebird says gene therapy 'very unlikely' cause of cancer case in trial; Vertex begins human testing for diabetes cell therapy View online | Signup | Forward

Gene Therapy weekly March​ 11,​ 2021 | This week's gene therapy news and insights for biopharma leaders   BROUGHT TO YOU BY — Catalent Catalent to Acquire Delphi Genetics Catalent will acquire Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy CDMO in Belgium, and launch pDNA manufacturing services in the US. Learn more.   How Rocket Pharma quietly became one of gene therapy's high flyers An unconventional strategy is behind the rise of Rocket, a New Jersey biotech whose executives boldly talk of turning into the "Genentech of gene therapy." Bluebird says gene therapy 'very unlikely' cause of cancer case in trial The biotech is discussing its findings with U.S. and European regulators in hopes of resuming study of the treatment as well as sales of a related product. BIOPHARMA DIVE TRENDLINE A closer look at the resurgence of gene therapy Explore the latest developments in gene therapy and why leading companies like Roche and Pfizer are once again investing in this area of biomedical research in this new Trendline. Vertex begins human testing for diabetes cell therapy While Vertex is confident in the therapy, which came via the $1 billion acquisition of Semma Therapeutics, it will still be a few years before the company has a good read on its effects in Type 1 diabetes patients. Read more news Featured Resources FROM: Catalent Partnering for Gene Therapy Development [Webinar] - Are Real-Time Gene Therapy Test Results Possible? [Webinar] - Navigating the Path to the Clinic and Beyond for Gene Therapies [Web Resource] - Why Catalent for Cell and Gene Therapy? From Our Library Trendline What you need to know about oncology's research boom View all resources What We're Reading The Guardian NHS to use world's most expensive drug to treat spinal muscular atrophy NPR Author Walter Isaacson On The Gene Editing Revolution Triangle Business Journal 200-job gene therapy project in Sanford progresses despite pandemic Endpoints News In race for in vivo sickle cell cure, Intellia unveils (very) early proof-of-concept Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Gene Therapy Weekly with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Gene Therapy Weekly. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Gene Therapy Weekly is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip